A Phase 1/2 Study of Ruxolitinib With Ulixertinib in People With Myelofibrosis

Full Title

Purpose

Ruxolitinib is used to treat myelofibrosis, a rare bone marrow cancer that disrupts your body’s normal blood cell production. Some people taking this drug, however, keep having symptoms. Researchers want to see if adding the drug ulixertinib to ruxolitinib treatment is safe and works better to treat myelofibrosis.

Ulixertinib works by blocking a protein called ERK, which promotes the growth and spread of cancer cells. By blocking ERK, ulixertinib may cause your cancer to stop growing or shrink. Both ulixertinib and ruxolitinib are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have myelofibrosis and have been experiencing symptoms after at least 3 months of taking ruxolitinib.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Raajit Rampal’s office at 646-608-3746.